Provider Briefing: Cartia XT and Diltiazem ER Availability in 2026

Your patients are calling about Cartia XT. They can't find it at their pharmacy, they're worried about running out, and they want to know if there's a shortage. As a prescriber, you need accurate, up-to-date information to guide clinical decisions and keep patients safely medicated.

This article provides a comprehensive overview of Cartia XT (Diltiazem Hydrochloride extended-release capsules) availability, the factors affecting supply, prescribing considerations, and practical tools to help your patients maintain access to their medication.

Current Availability Picture

As of early 2026, oral Cartia XT and generic Diltiazem ER capsules (Cardizem CD equivalent) are not listed on the FDA Drug Shortage Database. There is no formal nationwide shortage of the oral formulations.

However, localized availability issues persist. Pharmacies across the country report intermittent difficulty obtaining Cartia XT and certain generic Diltiazem ER products due to:

• Manufacturer allocation limits from Teva Pharmaceuticals (Cartia XT) and generic producers
• Distributor supply chain constraints
• Demand variability driven by insurance formulary changes

The injectable form of Diltiazem remains in a well-documented shortage dating back to June 2015, exacerbated by Akorn's discontinuation in mid-2022. Hikma and other manufacturers have products on allocation. This primarily affects inpatient settings but may contribute to patient anxiety about Diltiazem supply broadly.

Shortage Timeline and Context

Understanding the broader Diltiazem supply landscape helps inform clinical conversations:

• June 2015: Diltiazem injection shortage begins; multiple manufacturers affected
• Mid-2022: Akorn Operating Co. discontinues Diltiazem injection, worsening the IV shortage
• 2023–2024: ASHP lists Diltiazem injection among drugs in shortage for nearly 8 years. Oral formulations experience periodic regional disruptions.
• 2025: Hikma Diltiazem injection 10 mL vials on backorder; 5 mL and 25 mL on allocation. Oral Cartia XT and generics remain generally available but with localized gaps.
• 2026 (current): No FDA-listed shortage of oral products. Intermittent pharmacy-level stock-outs continue.

Prescribing Implications

The complexity of the Diltiazem extended-release product landscape presents unique prescribing challenges that directly affect patient access.

Non-Interchangeable Formulations

This is the most clinically significant issue. There are at least six distinct extended-release Diltiazem product types, and they are not interchangeable:

• Cardizem CD / Cartia XT / Dilt-CD type: ER capsules, once daily (120–360 mg)
• Tiazac / Taztia XT type: ER capsules, once daily (120–420 mg)
• Cardizem LA / Matzim LA type: ER tablets, once daily (120–360 mg)
• Dilacor XR / Dilt-XR type: ER capsules, once daily (120–240 mg)
• Cardizem SR type: SR capsules, twice daily (60–120 mg)
• Cardizem (immediate release): Tablets, 3–4 times daily (30–120 mg)

Each formulation has different pharmacokinetic profiles. Pharmacists cannot substitute across these categories without a new prescription. When writing prescriptions, specify the formulation type clearly (e.g., "Diltiazem ER capsules, Cardizem CD type") to give pharmacists maximum flexibility while ensuring bioequivalence.

Therapeutic Substitution Considerations

When Diltiazem ER (CD type) is unavailable, consider the patient's primary indication:

• Hypertension only: Amlodipine 5–10 mg daily is the most accessible alternative. Generic costs as low as $4/month. Note: Amlodipine does not provide rate control.
• Hypertension + rate control needed: Verapamil ER 180–360 mg daily is the most pharmacologically similar option. Consider Metoprolol Succinate ER 50–200 mg daily as an alternative class.
• Chronic stable angina: Amlodipine, Nifedipine ER, or a long-acting nitrate may be appropriate depending on the clinical scenario.
• Rate control (atrial fibrillation/flutter): Verapamil or a beta-blocker (Metoprolol Succinate ER) are standard alternatives.

For a patient-facing overview of alternatives, see alternatives to Cartia XT.

Cost and Access Considerations

Cost barriers compound availability issues. Here is the current pricing landscape:

• Brand Cartia XT (cash price): $70–$300+/month depending on strength
• Generic Diltiazem ER, CD type (with coupon): $10–$30/month
• Generic Diltiazem ER (retail cash, no coupon): ~$850/year ($70/month)
• Insurance coverage: Generic Diltiazem ER is widely covered as Tier 1/Tier 2. Brand Cartia XT may require prior authorization.

Patients without insurance or with high deductibles benefit significantly from discount programs (GoodRx, SingleCare, RxSaver). The Teva Cares Foundation offers patient assistance for eligible uninsured patients. Additional resources are available through NeedyMeds and RxAssist.

For provider-specific savings guidance, see how to help patients save money on Cartia XT.

Tools and Resources for Providers

Several tools can help you and your staff manage Cartia XT availability challenges:

Medfinder for Providers

Medfinder allows providers and clinical staff to check real-time pharmacy availability for Cartia XT and Diltiazem ER products. This can be integrated into your workflow when patients report difficulty filling prescriptions. Direct your patients to the platform, or use it proactively when writing prescriptions for medications with known availability issues.

FDA Drug Shortage Database

The FDA Drug Shortage Database provides official shortage listings and estimated resolution dates. Monitor this for any changes to oral Diltiazem ER status.

ASHP Drug Shortage Resource Center

ASHP maintains detailed shortage reports including alternative therapy recommendations and clinical guidance.

Prescription Writing Best Practices

To maximize your patient's chance of getting their medication filled:

• Write for "Diltiazem ER capsules (Cardizem CD equivalent)" rather than brand-only "Cartia XT" when clinically appropriate
• Allow generic substitution unless there's a specific clinical reason not to
• Include the DAW (Dispense As Written) code 0 to allow substitution
• Consider e-prescribing to multiple pharmacies if your system allows
• Proactively discuss availability with patients and provide backup plans

Looking Ahead

The Diltiazem market is unlikely to see major changes in 2026. The oral formulation supply appears stable at the national level, though localized disruptions will continue. The injectable shortage is expected to persist.

Key trends to watch:

• Insurance formulary decisions that may shift demand between Diltiazem products
• Any changes in Teva's manufacturing capacity for Cartia XT
• New generic entrants for the less common Diltiazem formulations
• Potential resolution of the injectable shortage as manufacturers expand capacity

Final Thoughts

While Cartia XT is not in an official shortage, your patients' difficulties finding it are real. As a prescriber, you can help by writing flexible prescriptions, being prepared with therapeutic alternatives, and directing patients to tools like Medfinder to locate available stock.

The most effective approach combines proactive prescribing practices with patient education. Ensure your patients understand the importance of early refills, know about discount programs, and have a backup plan if their regular pharmacy runs out.

For additional clinical information, see our articles on Cartia XT drug interactions and how to help your patients find Cartia XT in stock.